Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STP938 in High Risk Essential Thrombocythaemia
NCT06786234Phase 2Recruiting
- Sponsor
- StepPharma
- Start
- Jun 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of dencatistat in essential thrombocythemia (ET), sponsored by StepPharma. Primary endpoints: Clinical Efficacy at 12 months and Safety and Tolerability at 12 months. Started Jun 2025; status: recruiting.
02
Drugs
dencatistat
03
Conditions
essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT06786234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06786234.